Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 Deadly ... Therapeutics, the newest resident of the University City ... Street in Philadelphia. , With a $4.5 million ... Health in hand, Phelix Therapeutics is focused ... developing nutritional supplements. The company is developing first-in-class protease ...
(Date:4/27/2015)... 27, 2015 Editor ... scroll to bottom . Investor-Edge has ... Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals Inc. ... SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... ). Free research report on Lexicon Pharma can ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
(Date:4/27/2015)... HEIDELBERG , Germany ... Addresses unmet need in treatment of millions of cancer ... been granted a patent in Europe ... supports Molecular Health,s discovery that EPHB4 is a novel receptor ... tumor growth. EPO stimulates the production of red blood cells ...
Breaking Biology Technology:New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5SynGen Inc. Expands Its Management Team 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2
... into the human brain to understand its functions in ... illness — has long been a challenge for researchers. ... and sensors that can damage tissue while only reading ... Jonathan Viventi , assistant professor at ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... it will host an Investor and Analyst Day at NASDAQ ... 2:00 to 5:00 pm ET. Key members of the company,s ... specifically focusing on the recent commercial launch of the MaterniT21 ...
... Calif., Nov. 14, 2011 VIVUS, Inc. (NASDAQ: ... TA-314, a phase 3 long-term safety and efficacy study ... erectile dysfunction (ED), was presented over the weekend at ... Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, ...
Cached Biology Technology:Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 2Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 3Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 4Sequenom to Host Analyst Day on Monday, November 14, 2011 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 315-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 4
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... When a foreign object such as a catheter enters the ... into a slick coating a biofilm that is ... cannot be defeated by a basic approach of conventional means. ... reveals the key players in the network and how they ...
... 2010 China PharmaHub Corp. (OTC Bulletin Board: ... agreement to be a distributor for Integrated Biometrics ("IB"), ...  PharmaHub will have the exclusive distribution rights in China, ... to sell IB products to customers in the Pharmaceutical, ...
... soldiers in the battlefield healthy, the U.S. Army is exploring ... Current techniques for analyzing water in the field can take ... Lipkens of Western New England College in Springfield, Massachusetts and ... They are working on an alternative technology that uses sound ...
Cached Biology News:Research provides new leads in the case against drug-resistant biofilms 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 3
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
R26.4C...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Biology Products: